local_hospital

Centre Hospitalier Universitaire De Nimes

Address
lock Available on a paid plan

Cardiovascular and Metabolic Research

The clinical trial portfolio at Centre Hospitalier Universitaire De Nimes includes a strong focus on cardiovascular diseases and metabolic disorders, with studies in atherosclerotic cardiovascular disease, heart failure, hypertension, and diabetes-related complications. These trials are designed to test new treatments and prevention strategies, while also improving long-term risk reduction and patient outcomes.

  • Cardiovascular disease, including prevention of major events and recovery after acute episodes
  • Heart failure, hypertension, and vascular risk management
  • Metabolic conditions such as diabetic kidney disease and lipid-related risk

Research in this area also explores ways to better protect high-risk patients through improved treatment effectiveness and follow-up care.

Oncology and Hematology

A major part of the research activity at this site covers cancer and blood disorders, especially breast cancer, lung cancer, urothelial cancer, prostate cancer, and lymphomas. The studies aim to evaluate new anticancer therapies, improve disease control, and support better survival outcomes across both solid tumors and hematologic malignancies.

  • Breast cancer, including triple-negative and hormone receptor-positive disease
  • Leukemia, myelodysplastic syndromes, and myelofibrosis
  • Lymphomas, multiple myeloma, and other advanced blood cancers
  • Urothelial, prostate, lung, and head and neck cancers

Much of this work focuses on testing new treatment combinations and refining care for patients with advanced or hard-to-treat disease.

Neurology and Movement Disorders

The site conducts extensive research in neurological diseases, particularly multiple sclerosis, Parkinson’s disease, migraine, and other movement or cognitive disorders. These trials are aimed at slowing progression, reducing symptoms, and improving everyday functioning for people living with chronic neurological conditions.

  • Multiple sclerosis, including relapsing and progressive forms
  • Parkinson’s disease and related motor fluctuations
  • Migraine, tremor, and other movement disorders
  • Psychogenic non-epileptic seizures and cognitive impairment-related studies

This area reflects a broad effort to test therapies that may improve symptoms, preserve mobility, and support long-term neurological health.

Gastroenterology, Inflammation, and Autoimmune Disease

Clinical research at Centre Hospitalier Universitaire De Nimes also includes a strong presence in digestive system diseases and immune-mediated conditions. Key studies involve Crohn’s disease, ulcerative colitis, IgA nephropathy, and several autoimmune disorders, with the goal of improving disease control and reducing complications.

  • Crohn’s disease and ulcerative colitis
  • IgA nephropathy and other immune-related kidney diseases
  • Rheumatoid arthritis, juvenile idiopathic arthritis, and vasculitis
  • Inflammatory bowel disease recurrence prevention and symptom management

These trials commonly focus on better symptom control, preventing relapse, and evaluating more effective treatment approaches for chronic inflammatory illness.

Kidney, Urology, and Renal-Associated Research

Another important research stream involves kidney disease and urologic cancers, including chronic kidney disease, end-stage renal disease, glomerular diseases, and bladder cancer. The studies are intended to improve kidney function preservation, refine cancer care, and support better management of urinary tract conditions.

  • Chronic kidney disease, acute kidney injury, and dialysis-related care
  • IgA nephropathy, membranous nephropathy, and focal segmental glomerulosclerosis
  • Bladder, urothelial, and renal cell cancers
  • Urinary tract infections and related complications

Research in this field is centered on improving treatment effectiveness while limiting progression and recurrence.

Infectious Diseases, Critical Care, and Perioperative Research

The site participates in trials across infectious diseases, critical care, and perioperative medicine. Studies include COVID-19, septic shock, pneumonia, and serious bacterial infections, alongside research on anesthesia and surgical care. The overall aim is to improve survival, reduce complications, and optimize care for hospitalized patients.

  • Sepsis, septic shock, and severe hospital infections
  • Pneumonia and other respiratory infections
  • Perioperative anesthesia, pain control, and surgical support
  • Vaccine and infection-prevention studies

This area combines treatment evaluation with practical efforts to improve care in acute and high-risk clinical settings.

Psychiatry, Addiction, and Quality-of-Life Research

Research also extends into mental health and addiction medicine, with studies in major depressive disorder, schizophrenia, alcohol use disorder, and related behavioral conditions. These trials are generally aimed at testing new therapies, improving symptom relief, and supporting better daily functioning.

  • Depression and mood disorders
  • Schizophrenia and cognitive impairment
  • Alcohol dependence and substance use disorders
  • Brain function and symptom-focused supportive research

At this hospital site, these studies broaden the research profile beyond physical disease and into patient-centered mental health care.

Pediatric, Neonatal, and Reproductive Health

The research portfolio includes selected studies in neonatal, pediatric, and reproductive health areas. Conditions studied include preterm infant complications, respiratory distress in newborns, and pregnancy-related risks, with a focus on improving early-life care and maternal outcomes.

  • Preterm infants and feeding or respiratory complications
  • Pregnancy complications and high-risk obstetric care
  • Pediatric neurological and surgical conditions

These trials are designed to support safer care for vulnerable patients at the start of life and during pregnancy.

Site Overview

assignment
302
connected trials
corporate_fare
123
sponsors
science
529
IMPs

Activity Indicator

Last 6 months

32
Trials started
+39% vs previous period.
23
Trials started 6–12 months ago
302
Total trials linked
Highly Active
trending_upGrowing+39%
5
8
7
5
7
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 28 therapeutic areas and 15 of 529 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 469 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
197
Sponsors (total)
123
Active sponsors
89

Sponsor Network

Top 89 by active trials.

lock +88 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +50 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
302
Outperforms 97% of sites
public
Therapeutic diversity
30areas
Outperforms 97% of sites
groups
Sponsor diversity
123sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Universitaire De Nimes

lock Showing 1 of 302 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
"CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trialInstitut CuriePhase IINot Yet Recruiting

IMP list

lock Showing 1 of 529 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Sodium Chloride23Unknown2017-05-312026-06-24

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.